Quinazolinone and isoquinolinone acetamide derivatives
View Patent ↗Disclosed herein are quinazolinone or isoquinolinone derivatives of formula I, or pharmaceutically acceptable salts or solvates thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising quinazolinone or isoquinolinone according to the present invention and its use in therapy.
1. A compound of formula I,
wherein
R 1 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-3 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, said C 1-6 alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkylC 1-3 alkyl being optionally substituted with hydroxy, C 1-6 alkyloxy, cyano or one or more halogens;
R 2 is C 6-10 aryl optionally substituted with one to three substituents selected from halogen, hydroxy, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyloxy and C 3-6 cycloalkyloxy, said C 1-6 alkyl, C 3-6 cycloalkyl, alkyloxy and C 3-6 cycloalkyloxy being optionally substituted with one or more halogens;
or R 2 is a 5-10 membered heteroaryl ring system comprising a heteroatom selected from N, O and S and optionally substituted with a substituent selected from methyl, C 1-6 alkyloxy and halogen;
or R 2 is C 4-7 cycloalkyl;
R 3 is an optional substituent selected from C 1-6 alkyl, C 1-6 alkyloxy and halogen, said C 1-6 alkyl and C 1-6 alkyloxy being optionally substituted with one or more halogens;
R 4 is a group located at the 6- or 7-position of the quinazolinone or isoquinolinone ring having the formula II
wherein
R 5 is joined together with one of R 7 and R 8 to have the structure of formula II form a 1,4-diazepine ring optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo;
Each R 6 is independently H, halogen or C 1-4 alkyl optionally substituted with halogen or SO 2 CH 3 ;
R 7 and R 8 are independently H, C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-3 alkyl, cyanoC 1-3 alkyl, C 6-10 aryl, C 6-10 arylC 1-3 alkyl, C 1-3 alkyloxyC 1-3 alkyl or C 1-6 acyl said C 1-6 alkyl, C 3-6 cycloalkyl and C 3-6 cycloalkylC 1-3 alkyl being optionally substituted with hydroxy, 1 or more halogens or diC 1-2 alkylamino;
Each R 12 is independently H or C 1-4 alkyl;
m is 2 or 3; and
X is N or CH,
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein R 1 is isopropyl, isobutyl, tertiary-butyl, cyclopropylmethyl, cyclobutyl, 2,2,2-trifluoro-1-methylethyl or 2,2,2-trifluoro-1,1-dimethylethyl.
3. The compound according to claim 1 , wherein R 2 is a substituted phenyl ring selected from 3-chlorophenyl, 3-fluorophenyl, 3-methoxyphenyl, 3-trifluoromethoxyphenyl, 3-chloro-4-fluorophenyl, 4-fluoro-3-methoxyphenyl and 3,5-dimethoxyphenyl.
4. The compound according to claim 1 , wherein R 4 is a group selected from
wherein R 6 , R 7 and R 12 have the previously defined meanings.
5. The compound according to claim 1 , wherein X is N and R 4 is a substituent at the 6-position.
6. The compound according to claim 1 , wherein X is N.
7. A compound selected from:
2-[2-(3-Chlorophenyl)-4-oxo-6-perhydro-1,4-diazepin-1-yl-4H-quinazolin-3-yl]-N-isopropylacetamide;
N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-perhydro-1,4-diazepin-1-yl-4H-quinazolin-3-yl]acetamide;
N-tert-Butyl-2-(2-(3-chloro-4-fluorophenyl)-6-(1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)acetamide;
2-(2-(3-Chloro-4-fluorophenyl)-6-(1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-isopropylacetamide;
2-(2-(3-Chloro-4-fluorophenyl)-6-(3-methyl-1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-(3-ethylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-(dimethylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[6-(Dimethylperhydro-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-((S)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chlorophenyl)-6-((S)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(4-Fluoro-3-methoxyphenyl)-6-((S)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-((R)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chlorophenyl)-6-((R)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(4-Fluoro-3-methoxyphenyl)-6-((R)-3-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chlorophenyl)-6-(4-methylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[6-(4-Ethylperhydro-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chlorophenyl)-4-oxo-6-(4-propylperhydro-1,4-diazepin-1-yl)-4H-quinazolin-3-yl]-N-isopropylacetamide;
N-tert-Butyl-2-[6-(4-ethylperhydro-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide;
2-[2-(3-Chlorophenyl)-6-(4-ethylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[6-(4-Ethylperhydro-1,4-diazepin-1-yl)-2-(4-fluoro-3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(4-Fluoro-3-methoxyphenyl)-4-oxo-6-(4-propylperhydro-1,4-diazepin-1-yl)-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-(4-ethylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
N-Isopropyl-2-[6-(4-isopropylperhydro-1,4-diazepin-1-yl)-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]acetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-(4-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-5-trifluoromethylphenyl)-4-oxo-6-perhydro-1,4-diazepin-1-yl-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3,5-Dimethoxyphenyl)-6-(4-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide;
2-[2-(3-Chloro-4-fluorophenyl)-6-{4-(1-cyclopropylethyl)perhydro-1,4-diazepin-1-yl]-4-oxo-4H-quinazolin-3-yl}-N-isopropylacetamide;
2-{2-(4-Fluoro-3-methoxyphenyl)-6-[4-(2-hydroxyethyl)perhydro-1,4-diazepin-1-yl]-4-oxo-4H-quinazolin-3-yl}-N-isopropylacetamide;
2-{2-(3-Chloro-4-fluorophenyl)-6-[4-(2-hydroxyethyl)perhydro-1,4-diazepin-1-yl]-4-oxo-4H-quinazolin-3-yl}-N-isopropylacetamide;
2-[2-(3-Chlorophenyl)-6-(4-isopropylperhydro-1,4-diazepin-1-yl)-4-oxo-4H-quinazolin-3-yl]-N-(2,2,2-trifluoro-1,1-dimethylethyl)acetamide;
N-Isopropyl-2-(6-(4-isopropyl-1,4-diazepan-1-yl)-2-(3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl)acetamide;
2-(2-(3-Chlorophenyl)-6-(4-cyclopropylmethyl-1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-isopropylacetamide and
N-tert-Butyl-2-(2-(3-chlorophenyl)-6-(4-isopropyl-1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)acetamide
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with and one or more pharmaceutically acceptable auxiliaries.
9. A pharmaceutical composition comprising a compound according to claim 7 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable auxiliaries.
10. 2-(2-(3-Chlorophenyl)-6-(4-cyclopropylmethyl-1,4-diazepan-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-isopropylacetamide.
11. A pharmaceutical composition comprising a compound according to claim 10 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable auxiliaries.